cis-Rose oxide is a monoterpene ether reported as a minor constituent in essential-oil GC-MS profiles.
Aroma and practical use
No aroma description is attached to this identity yet.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
There are no constituent-specific outcome findings in this report. No therapeutic benefit is inferred from its presence.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Screening assumption (unrestricted). It is not a verified constituent-specific exposure limit.
model fallback · IFRA Standards, 51st Amendment (Jan 2024) - rose oxide (CAS 16409-43-1) not listed among restricted materials, per ScenTree ingredient page IFRA summary (https://www.scentree.co/en/Rose_oxide.html)Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Minor GC-MS constituent added during composition completion; profile/SEO detail pending. Dermal-restriction status resolved 2026-07-13: ScenTree confirms rose oxide (CAS 16409-43-1, listed there as '(Z)-rose oxide') carries no IFRA restriction under the 51st Amendment and no allergen labelling. Read-across caveat: CAS 16409-43-1 is used industrially for the 'BRI' rose oxide material (predominantly cis, sold as 'sum of isomers', e.g. Bedoukian 'ROSE OXIDE BRI 99.0% (sum of isomers)'), so this is the best available identity/registry match for cis-rose-oxide but may not represent an isomerically pure cis-only assessment; no Tisserand & Young monograph entry or quantitative IFRA leave-on percentage was located, so dermal_limit_pct stays null even though the material is unrestricted.
- No constituent-specific outcome findings are available in this report.
- No cited aroma description is available for this identity.
- No public source links are attached to this constituent report.
- No constituent-specific numeric dermal reference is available here.